Recent evidence suggests that belatacept reduces the durability of preexisting antibodies to class I and class II human leukocyte antigens (HLAs). In this case series of 163 highly sensitized kidney transplant candidates whose calculated panel-reactive antibody (cPRA) activity was ≥98% to 100%, the impact of belatacept on preexisting HLA antibodies was assessed. Of the 163 candidates, 72 underwent transplantation between December 4, 2014 and April 15, 2017; 60 of these transplanted patients remained on belatacept consecutively for at least 6 months. We observed a decrease in the breadth and/or strength of HLA class I antibodies as assessed by FlowPRA in belatacept-treated patients compared to controls who did not receive belatacept. Specifically, significant HLA antibody reduction was evident for class I (P < .0009). Posttransplant belatacept-treated patients also had a clinically significant reduction in their cPRA compared to controls (P < .01). Collectively, these findings suggest belatacept can reduce HLA class I antibodies in a significant proportion of highly sensitized recipients and could be an option to improve pretransplant compatibility with organ donors.

This chapter presents the environment of U.S. GAAP research and important databases with a focus on the Financial Accounting Standards Board (FASB's) codification research system. Research on accounting issues is conducted in a dynamic and complex environment where new professional standards are issued and existing standards are updated or deleted. As U.S. GAAP is a fluid set of principles based on current accounting thought and practice, and not a static, well-defined set of accounting principles, accountants must research updates to the codification or changes in the pronouncements. The codification has consolidated U.S. GAAP down to two levels; however, there are still many sources. One needs to use the codification to find relevant authorities. Thus, one must understand how the databases are structured, their contents, and search techniques.

We hypothesized that zero calcium score (ZCS) would predict normal myocardial perfusion SPECT in patients with end stage renal disease (ESRD) undergoing evaluation for renal transplant. We enrolled 354 consecutive patients (65% men, mean age 52 ± 11 years) without known coronary artery disease

Preface iv About the Authors vi Chapter 1 FASB Accounting Standards Codification Research System 1 Chapter 2 Electronic International Financial Reporting Standards 18 Chapter 3 Other Research Databases 31 Chapter 4 Knowledge Busters 41 Chapter 5 Introduction to Research and Case Analysis 55 Index 99

THE receptor-ligand pairs CD28-B7 and CD40-gp39 are essential For the initiation and amplification of T-cell-dependent immune responses(1,2). CD28-B7 interactions provide 'second signals' necessary for optimal T-cell activation and IL-2 production(3-5), whereas CD40-gp39 signals co-stimulate B-cell, macrophage, endothelial cell and T-cell activation(6-12). Nonetheless, blockade of either of these pathways alone is not sufficient to permit engraftment of highly immunogenic allografts(13-15). Here we report that simultaneous but not independent blockade of the CD28 and CD40 pathways effectively aborts T-cell clonal expansion in vitro and in vivo, promotes long-term survival of fully allogeneic skin grafts, and inhibits the development of chronic vascular rejection of primarily vascularized cardiac allografts. The requirement for simultaneous blockade of these pathways for effective inhibition of alloimmunity indicates that, although they are interrelated, the CD28 and CD40 pathways are critical independent regulators of T-cell-dependent immune responses.

Background: Urinary bladder rupture is a complication of both blunt and penetrating trauma. Significant morbidity and mortality can result from a missed rupture and its ensuing complications. Patients who are at risk for traumatic bladder rupture should undergo appropriate testing to expedite the diagnosis. Current diagnostic modalities include computed tomography (CT) cystography, and retrograde cystography. Although these modalities carry a sensitivity and specificity of 95-99% and 95-100%, their utility is limited by the resources and staff available. Furthermore, both techniques require that a potentially hemodynamically unstable trauma patient be transported out of the Emergency Department for the entire duration of the procedure. Objective: The following case report reviews the incidence and management of traumatic bladder rupture and describes how emergency physicians (EP) can use ultrasound to make this diagnosis quickly and safely at the bedside. Case Report: The case report describes a patient involved in a motor vehicle collision with a history concerning for urinary bladder injury. A bedside ultrasound study performed by the EP was used to establish the diagnosis of urinary bladder rupture. The ultrasound demonstrated a small contracted urinary bladder with copious free fluid anterior to the bladder wall. The diagnosis was confirmed by CT and the patient was taken expeditiously to the operating room. Conclusion: This case provides an example of how bedside ultrasound can be used to make an accurate and timely diagnosis of urinary bladder rupture and help expedite patient care. (C) 2011 Elsevier Inc.

Blockade of the CD40/CD154 signaling pathway using anti-CD154 Abs has shown promise in attenuating the alloimmune response and promoting long-term graft survival in murine model systems, although side effects observed in humans have hampered its progression through clinical trials. Appropriately designed anti-CD40 Abs may provide a suitable alternative. We investigated two isoforms of a novel monoclonal rat anti-mouse CD40 Ab (7E1) for characteristics and effects mirroring those of anti-CD154: 7E1-G1 (an IgG1 isotype); and 7E1-G2b (an IgG2b isotype). In vitro proliferation assays to measure the agonist properties of the two anti-CD40 Abs revealed similar responses when plate bound. However, when present as a soluble stimulus, 7E1-G1 but not 7E1-G2b led to proliferation. 7E1-G2b was as effective as anti-CD154 when administered in vivo in concert with CTLA4-Ig in promoting both allogeneic bone marrow chimerism and skin graft survival, whereas 7E1-G1 was not. The protection observed with 7E1-G2b was not due to depletion of CD40-bearing APCs. These data suggest that an appropriately designed anti-CD40 Ab can promote graft survival as well as anti-CD154, making 7E1-G2b an attractive substitute in mouse models of costimulation blockade-based tolerance regimens.

Shen, L; Agarwal, A; Turgeon, N; Pearson, T; Larsen, C; Bray, R; Gebel, H; Kirk, A; Kokko, K Author Information

Transplantation: July 27, 2008 - Volume 86 - Issue 2S - p 410 doi: 10.1097/01.tp.0000331474.40601.7d

Recent work by several groups defines the important role of the Toll-like receptors in alloimmunity. Identification of Toll-like receptors (TLRs) has stimulated research focused on increasing our understanding of the interactions between innate and adaptive immune responses in alloimmunity (1). TLRs represent a cluster of molecules that can recognize pathogen-associated as well as endogenous molecular patterns. Mechanistic studies on intracellular signal transduction have revealed that upon ligation TLRs can trigger intracellular signals by engaging adaptor proteins such as MyD88-dependent and Myd-88-independent (TRIF, TRAM-mediated) signal transduction pathways ultimately leading to increased expression of proinflammatory cytokines and other inflammatory mediators (1). Recent work by three groups, point both, to the importance of the TLR pathway in alloimmunity and the possibility that this effect may occur via multiple mechanisms. A remarkable study by McKay et al. studied the role of TLR signaling in allograft rejection in the absence of immune modulation (2). These investigators utilized mice with deletions of the proximal TLR adaptor proteins (Myd88 and TRIF) and found that prolonged survival of full MHC and multiple minor antigen-mismatched skin allografts from double knockout mice donors was associated with diminished migration of donor cells to draining lymph nodes and delayed infiltration of host T cells into the allograft. The authors suggest that their data support the importance of TLR pathways in the activation and migration of donor antigen presenting cells from allografts. In the second study Thornley and colleagues, investigated the role of TLR signaling on an anti-CD154 based regimen to prolong the survival of mouse skin allografts (3). This strategy, donor-specific transfusion and anti-CD154, has previously been shown to delete graft-specific CD8+ T cells and promote long-term graft survival (4). The current study showed that administration of TLR agonists or LCMV infection prior to the tolerance regimen led to decreased survival of skin allografts, which was associated with impaired deletion of alloreactive CD8+ T cells. Using the ‘synchimera’ mouse model (KB5 TCR-transgenic hemopoietic chimeras), the authors show that the effect of TLR agonist to shorten the skin allograft survival required the presence of CD8+ T cells and that TLR agonist protects alloreactive CD8+ T cells from apoptosis in this model. In the recent issue of American Journal of Transplantation, an eloquent paper by Chen and colleagues highlights the significance of TLR signaling in transplantation by investigating the hypothesis that commensal microbes capable of stimulating TLRs can augment alloresponse and prevent tolerance induction (5). The authors analyzed the mouse heterotopic heart model that is normally susceptible (no commensal microbes) and the skin transplant model that is normally resistant (with commensal microbes) to costimulation blockade (anti-CD154)-based therapy. They tested the ability of TLR engagement using TLR agonists to augment cardiac allograft rejection, and the ability of Myd88-deficient mice (diminished TLR signaling) to prolong skin graft survival. Their results show that the TLR9 or TLR2 agonists trigger CD4-dependent rejection of allogeneic heart grafts, and that the TLR9 agonist prevents an increase in regulatory T cells (CD4+FoxP3+ T cells) and induction of regulation. Furthermore, allogenieic skin grafts from Myd88-deficient donors to Myd88-deficient recipient mice with anti-CD154 treatment led to long-term survival of allografts, suggesting that inhibition of TLR signaling can facilitate long-term survival of grafts that are otherwise resistant to a costimulation blockade-based tolerance regimen. These findings clearly highlight the importance of TLR signaling in costimulation blockade strategies for the prolongation of allograft survival. These results suggest that the TLR agonist prevented the intragraft recruitment of CD4+FoxP3+ cells and that TLR engagement may influence the adaptive immune response by regulatory T-cell-mediated suppression. As the authors point out, this is not necessarily an exclusive mechanism as, for example, the TLR agonist may enhance the function of T cells in such a way that the T effectors become resistant to the effects of regulatory T cells. These three elegant studies define the importance of TLR signaling in alloimmunity. Importantly, they also highlight three distinct mechanisms by which innate immunity influences allograft survival: (i) regulatory T-cell-mediated suppression, (ii) modulation of the activation and migration of donor antigen presenting cells and thus delayed infiltration of host T cells into the graft and (iii) impaired peripheral deletion of alloreactive CD8+ T cells. Future studies to further define these mechanisms will be of critical importance for the rational development of strategies to target TLR signaling as a means to improve clinical immunosuppressive regimens or as a component of tolerance induction strategies. Understanding the important role of TLR signaling is also very important for experimental transplantation. Heterologous immunity, in which previous exposure to pathogens alters the transplant recipient's T-cell repertoire to produce, for example, virally induced alloreactive T-cell memory has been defined as one means by which the environment can modulate the alloimmune response (6). The definition of the ability of commensal microbes or environmental pathogens to alter the alloimmune response via TLR pathways further highlights the importance of the environment to a transplant recipient's immune response. This has significant implications for the interpretation of experimental results obtained in mice housed in specific pathogen-free conditions versus large animal models and clinical trials. Thus while the important studies discussed above suggest intricate mechanisms by which innate and adaptive immune responses communicate, they also emphasize how the microbial environment in which the alloimmune response occurs can dictate resistance versus susceptibility to costimulation blockade-based therapies. Further studies addressing the role of innate immunity in clinically applicable treatment regimens provide an exciting opportunity to enhance our understanding of when and where innate immune responses can be modulated to achieve long-term graft survival and perhaps tolerance.

Hedge funds are complex financial products which have grown exponentially during the past decade. While hedge funds provide benefits to the world's capital markets, they also pose challenges. The potential risk to the stability of the world's financial system combined with an increase in hedge fund fraud led the Securities and Exchange Commission (SEC) to attempt to regulate hedge fund advisers. After the court rejected the SEC's expansion of its regulation, the SEC adopted regulations that insufficiently address the problems posed by hedge funds. This article proposes more effective solutions involving a coordinatedinternational approach to hedge fund regulation. The hedge fund regulations proposed in this article aim to achieve a reliably stable financial system, financial market integrity through greater transparency, and protection for all investors from fraud.

In September 2005, an National Institutes of Health-sponsored workshop was held in Atlanta, Georgia, which focused on non-human primate transplantation tolerance models. The aim of this workshop was an open exchange of techniques and assays applicable to this important translational transplantation model. A major focus of the workshop was the development of assays that are capable of monitoring immune status after transplant. These include mixed lymphocyte reaction assays (using both tritiated thymidine and carboxyfluorescein succinimidyl ester to assess T-cell proliferation), large-scale production of dendritic cells for immune analysis, the molecular analysis of graft rejection and acceptance using single-plex RNA analysis, and multiplex flow cytometric and gene array analysis, as well as sophisticated multi-color flow cytometric profiling of immunocyte subpopulations and cytokine expression patterns. This review will summarize the progress presented at the workshop toward the application of these techniques to immune analysis in non-human primates and discuss their relative contributions to ongoing evaluation of immune tolerance after transplantation.

hosts. 2 weeks later, alloimmune priming of recipient T cells was measured by ELISPOT. Results show that mice injected with DCs exposed to media from TLR activated neonatal B cells manifest inferior IL-2 and IFNγ T cell responses vs. those injected with DCs exposed to media from TLR activated adult B cells. Conclusion Neonatal, but not adult B cells possess unique immunoregulatory properties that inhibit alloimmunity and may explain the tolerance-prone state of the neonate.

Current success in organ transplantation is dependent upon the use of calcineurin-inhibitor-based im-munosuppressive regimens. Unfortunately, current immunotherapy targets molecules with ubiquitous ex-pression resulting in devastating non-immune side effects. T-cell costimulation has been identified as a new potential immunosuppressive target. The best characterized pathway includes CD28, its homologue CTLA4 and their ligands CD80 and CD86. While an im-munoglobulin fusion protein construct of CTLA4 sup-pressed rejection in rodents, it lacked efficacy in primate transplant models. In an attempt to increase the biologic potency of the parent molecule a novel, modified version of CTLA4-Ig, LEA29Y (belatacept), was constructed. Two amino acid substitutions (L104E and A29Y) gave rise to slower dissociation rates for both CD86 and CD80. The increased avidity resulted in a 10fold increase in potency in vitro and significant prolongation of renal allograft survival in a pre-clinical primate model. The use of immunoselective biologics may provide effective maintenance immunosuppression while avoiding the collateral toxicities associated with conventional immunsuppressants.

Adams, Andrew B; Shirasugi, Nozomu; Strobert, Elizabeth A2; Cowan, Shannon R; Rees, Phyllis A; Hendrix, Rose; Kenyon, Norma S3; Pearson, Thomas C; Larsen, Christian P Author Information

Tolerance‐inducing strategies that infuse donor bone marrow cells in conjunction with costimulation blockade have not been applied to intestinal transplantation. Intestines from BALB/c mice were transplanted into C57BL/6 recipients treated with anti‐CD40L mAb, CTLA4‐Ig, donor bone marrow, and busulfan. The majority of mice transplanted after completion of this regimen developed hematopoietic macrochimerism, although the degree of chimerism varied widely between recipients, and experienced long‐term allograft survival. T cells from these mice demonstrated donor‐specific hyporesponsiveness in vitro. However, T cells from chimeric mice proliferated to donor alloantigen in vivo. Furthermore, chimeric mice bearing intestinal allografts were capable of rejecting subsequently placed donor‐strain skin grafts. These data suggest that although long‐term allograft survival occurs in the absence of acute or chronic rejection, recipient mice are not completely unresponsive to donor alloantigens. When intestinal transplantation was performed at the time of initial bone marrow infusion (initiation of the chimerism protocol), most recipients failed to develop chimerism and promptly rejected the intestinal allograft. Although this is the most effective protocol that we have tested using this stringent model of transplantation, our observations suggest that modifications will be necessary before it can be reliably applied to the transplantation of highly immunogeneic organs like the intestine.

The establishment of immune tolerance to self antigen expressed exclusively in the periphery is a crucial yet incompletely understood feature of the immune system. A dominant concept of peripheral tolerance has been that exposure of T cells to signal one, the TCR–MHC interaction, in the absence of signal two, or costimulation, is a major mechanism of peripheral tolerance. This model suggests that any cell type that expresses MHC-peptide complexes, be they of self or foreign origin, should have the capacity to tolerize antigen-specific T cells when critical costimulatory interactions are interrupted. However, a spectrum of responses, from permanent engraftment to rapid rejection, has been observed in various transplantation models utilizing costimulatory blockade. Therefore we undertook a series experiments to directly assess the tolerogenic potential of donor hematopoietic and parenchymal cells. We find that allogeneic tissues differ profoundly in their ability to promote peripheral tolerance concurrent with combined blockade of B7-CD28 and CD40-CD40L pathways. Non-vascularized and vascularized parenchymal grafts as well as donor-specific transfusions promote varying degrees of donor-specific hyporesponsiveness, but fail to induce donor-reactive T-cell deletion; whereas establishment of stable hematopoietic chimerism promotes specific tolerance mediated by deletion of donor-reactive cells in the periphery.

T-cell costimulatory blockade has emerged as an effective strategy to prevent allograft rejection in experimental models. We and others have reported that the beneficial effects of costimulation blockade can be negated when combined with certain immuno-suppressants. The current study evaluates the compatibility of various immunosuppressive agents in a costimulation blockade-based, mixed chimerism tolerance protocol.The addition of conventional agents, including calcineurin inhibitors, did not interfere with tolerance induction. All mice developed multilineage macrochimerism and accepted donor allografts. Analysis of specific T-cell receptor utilization demonstrated selective deletion of donor-reactive T cells. Challenge with donor and third-party allografts confirmed donorspecific tolerance.Clinical introduction of costimulation blockade-based strategies will likely incorporate currently approved immunosuppressive agents. While it has been reported that certain conventional agents are detrimental to costimulation blockade-based strategies, our results suggest that these agents could safely be combined in clinical trials when used as part of a nonmyelosuppressive, mixed chimerism-based tolerance strategy.